Compare ResMed Inc. (RMD) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Synchrony Financial — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Synchrony Financial trades at $77.5 (market cap $25.58B). The key difference: ResMed Inc. is the larger of the two by market cap, and Synchrony Financial pays the higher dividend (1.73%). Which is the better fit depends on your goals.
| RMD | SYF | |
|---|---|---|
Market Cap | $31.89B | $25.58B |
Sector | Health | Financials |
52-Week High | $283.28 | $88.47 |
52-Week Low | $182.82 | $63.78 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 8.06 and robust profitability, including a 23.4% net income margin and 22.23% ROE. Recent earnings beats and a strategic partnership with OpenAI for AI-driven commerce highlight growth initiatives. Analyst consensus is bullish with a $87.33 price target and no sell ratings.
The outlook remains positive given valuation appeal, consistent earnings performance, and AI partnership potential. Key risks include consumer credit deterioration amid economic uncertainty and increased investing cash outflows. Institutional ownership trends and strong buyback activity support the bullish case, but credit quality monitoring is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
